Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 27, 2014

View Archived Issues

Apceth begins first human trial of genetically modified MSCs in cancer

Experience with tau-binding radiotracer [18F]T-807 accumulates

CHMP issues opinion on ataluren in nonsense mutation DMD

Researchers at Lundbeck present new nAChR PAMs

Endocyte provides update on MAAs for vintafolide and etarfolatide

GSK receives positive CHMP opinion for albiglutide in type 2 diabetes

Novel orexin receptor antagonists designed at Heptares Therapeutics

GSK reports data from phase III study of Tafinlar and Mekinist in melanoma

Canadian group discloses novel BTK inhibitors

hHR21 expression linked to prognosis in patients with colorectal cancer

Japanese researchers divulge new sst2 receptor agonists

Researchers at Esteve have patented novel sigma1R ligands

Crown Bioscience discloses novel kinase inhibitors for cancer

NIBIO, Aeras and Create form global collaboration to advance new mucosal TB vaccines

EMA committee recommends approval of Finox Biotech's biosimilar FSH

Roche's subcutaneous MabThera recommended for approval by CHMP

Lurasidone recommended for treatment of schizophrenia by EMA advisory committee

EMA committee recommends against approval of Nerventra for relapsing-remitting MS

Pacgen to sublicense global rights to antimicrobial peptide to GBC

mRNAs investigated as biomarkers in pancreatic neuroendocrine tumors

EMA committee advises against approval of masitinib for advanced pancreatic cancer

Nihon Medi-Physics launches DatSCAN in Japan

Phase I/II study of OPB-111001 recruiting patients with advanced cancer

Phase I study of novel treatment candidate for alcoholism begins patient recruitment

EMA committee recommends approval of Bayer's riociguat for two forms of pulmonary hypertension

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...